

Research

Open Access

The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis

Kwok M Ho¹, Jeffrey Lipman², Geoffrey J Dobb³ and Steven AR Webb⁴

¹Consultant Intensivist, Department of Intensive Care, Royal Perth Hospital, Australia

²Professor and Head of the Department, Department of Intensive Care Medicine, Royal Brisbane Hospital, University of Queensland, Australia

³Acting Head of the Department, Department of Intensive Care, Royal Perth Hospital, Australia and Associate Professor, School of Medicine and Pharmacology, University of Western Australia, Australia

⁴Consultant Intensivist, Department of Intensive Care, Royal Perth Hospital, Australia and Senior Lecturer, School of Medicine and Pharmacology, University of Western Australia, Australia

Corresponding author: Kwok M Ho, kwok.ho@health.wa.gov.au

Received: 23 Aug 2005 Accepted: 28 Sep 2005 Published: 25 Oct 2005

Critical Care 2005, **9**:R710-R717 (DOI 10.1186/cc3883)

This article is online at: <http://ccforum.com/content/9/6/R710>

© 2005 Ho *et al.*; licensee BioMed Central Ltd.

This is an open access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Introduction High-risk surgical patients are at increased risk of fungal infections and candidaemia. Evidence from observational and small randomised controlled studies suggests that prophylactic fluconazole may be effective in reducing fungal infection and mortality. We evaluated the effects of prophylactic fluconazole on the incidence of candidaemia and hospital mortality in immunocompetent high-risk surgical patients.

Methods Randomised controlled studies involving the use of fluconazole in immunocompetent high-risk surgical patients from the Cochrane Controlled Trial Register (2005, issue 1) and from the EMBASE and MEDLINE databases (1966–30 April 2005), without any language restriction, were included. Two reviewers reviewed the quality of the studies and performed data extraction independently.

Results Seven randomised controlled studies with a total of 814 immunocompetent high-risk surgical patients were considered. The use of prophylactic fluconazole was associated

with a reduction in the proportion of patients with candidaemia (relative risk [RR] = 0.21, 95% confidence interval [CI] = 0.06–0.72, $P = 0.01$; $I^2 = 0\%$) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, $P = 0.0003$; $I^2 = 0\%$), but was associated with only a trend towards a reduction in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, $P = 0.15$; $I^2 = 7\%$). The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17–0.72, $P = 0.004$; $I^2 = 0\%$). The proportion of patients colonised with or infected with fluconazole-resistant fungi was not significantly different between the fluconazole group and the placebo group (RR = 0.66, 95% CI = 0.22–1.96, $P = 0.46$; $I^2 = 0\%$).


Conclusion The use of prophylactic fluconazole in immunocompetent high-risk surgical patients is associated with a reduced incidence of candidaemia but with only a trend towards a reduction in hospital mortality.

Introduction

Fungi are an increasingly important cause of nosocomial infections in intensive care units (ICUs) [1,2]. Systemic fungal infections are difficult to diagnose and are associated with substantial morbidity, attributable mortality, prolonged hospital stay, and healthcare costs [1–6]. Despite advances in medical technology and the development of new antifungal drugs, the crude and attributable mortality of candidaemia has remained unchanged in the past 20 years [7]. *Candida* spp. remain the commonest type of fungal infections in the ICUs and candi-

daemia accounts for 15% of all nosocomial bloodstream infections in the United States [1], with similar trends being reported worldwide [8].

The use of prophylactic antifungal therapy in ICU is controversial, although evidence from observational studies suggests that antifungal prophylaxis is associated with a reduced risk of candidaemia [9]. The risk factors associated with candidaemia are prevalent in high-risk or critically ill surgical patients, and these include the presence of a central venous catheter, acute

Figure 1

Flow chart showing study inclusion and exclusion in this meta-analysis.

renal failure, total parenteral nutrition, gastrointestinal perforation, and prior surgery [9,10]. Antifungal prophylaxis appears more beneficial for non-neutropenic critically ill surgical patients than for critically ill medical patients [10,11].

An antifungal agent selected for prophylaxis should have an appropriate spectrum of activity, should be easily delivered, and should have few adverse events [11]. Fluconazole appears suitable and its efficacy has been evaluated in several randomised controlled clinical trials involving high-risk surgical patients, with variable results. In addition to its antifungal activity, fluconazole has been demonstrated to bind to neutrophil surface receptors and to upregulate intracellular signalling pathways, leading to enhanced oxygen free radical release and chemotaxis *in vitro* [12]. It has been postulated that this immunomodulation effect may explain, at least in part, the beneficial effect of fluconazole on clinical outcome in patients with gut perforation [13]. We conducted a meta-analysis to investigate the effects of prophylactic fluconazole on the incidence of candidaemia and hospital mortality in immunocompetent high-risk surgical patients.

Materials and methods


The literature search was performed on the Cochrane Controlled Trials Register (2005, issue 1) and the EMBASE and MEDLINE databases (1966–30 April 2005). Only randomised control clinical trials involving immunocompetent critically ill or high-risk surgical adult patients were included. For studies involving a mixture of surgical and non-surgical patients, only data from the surgical subgroup of patients were retrieved if possible. Studies involving the use of fluconazole antifungal prophylaxis for liver transplantation or for neutropenic cancer patients were excluded because they included immunosuppressed patients.

During the electronic database search, the following exploded MeSH terms were used: 'fluconazole' or 'antifungal' with 'critically ill', 'intensive care', 'trauma' or 'burns'. The reference lists of related reviews and identified original articles were searched for relevant trials. Finally, to ensure all suitable studies were included, the websites of the International Network of Agencies of Health Technology Assessment and the International Society of Technology Assessment in Health Care were searched and the company manufacturing fluconazole (Medical Department, Pfizer Australia Pty. Ltd., West Ryde NSW


Table 1**Characteristics of the included studies**

Study	Design	Participants	Interventions	Outcomes	Allocation concealment
Garbino <i>et al.</i> [15]	Double-blind	220 patients, mixture of surgical and medical critically ill adult patients; mean age = 54 years, mean APACHE II score = 19.4, mean ICU stay = 8.4 days, mean mortality = 39.5%	Intravenous fluconazole 100 mg/day until a fungal infection developed, withdrawn from mechanical ventilation, or suspicion of a serious adverse event. Duration of study = 30 months	Hospital mortality, proportion of patients with candidaemia, other fungal infections, adverse events requiring cessation of study drug, and patients required rescue therapy using systemic amphotericin B	Adequate
Pelz <i>et al.</i> [16]	Double-blind	260 critically ill surgical adult patients; mean age = 64 years, mean APACHE III score = 64, mean ICU stay = 5 days, mean mortality = 11.5%	Loading dose of 800 mg enteral fluconazole followed by 400 mg daily (reduced to 200 mg daily if creatinine clearance <25 ml/min) until 3 days after ICU discharge, or death, or clinical decision to start systemic antifungal therapy. Duration of study = 12 months	Hospital mortality, proportion of patients with candidaemia, and fungal infections, proportion of patients requiring rescue therapy using amphotericin B, proportion of patients colonised with or infected with fluconazole-resistant fungi, and the total length of hospital stay	Adequate
Eggimann <i>et al.</i> [17]	Double-blind	43 surgical adult patients with recurrent gut perforation or anastomotic leakage; mean age = 63 years, mean APACHE II score = 13, mean hospital mortality = 39.5%	400 mg intravenous fluconazole daily until complete resolution of the intra-abdominal disease, or development of a fungal infection requiring antifungal therapy, or adverse event related to the study drug. Duration of study = 30 months	Hospital mortality, proportion of patients with candidaemia and other fungal infection, proportion of patients with adverse events leading to cessation of study drug, proportion of patients colonised with or infected with fluconazole-resistant fungi, and the total length of hospital stay	Adequate
Sandven <i>et al.</i> [18]	Double-blind	109 high-risk surgical patients with a confirmed intra-abdominal perforation; mean age = 64 years, mean hospital mortality = 11.3%	A single dose of intravenous fluconazole 400 mg intraoperatively. Duration of study 15 months	Hospital mortality, and proportion of patients with fungal infection	Adequate
He <i>et al.</i> [19]	Unclear	45 adult patients with severe pancreatitis with at least one organ dysfunction or hyperglycaemia; mean age = 50 years, mean hospital mortality = 20%	Intravenous fluconazole 100 mg/day until no organ failure was observed. Duration of study = 60 months	Hospital mortality, proportion of patients with fungal infection, proportion of patients requiring rescue therapy using amphotericin B, and total length of hospital stay	Unclear
Jacobs <i>et al.</i> [13]	Double-blind	34 patients with septic shock from intra-abdominal sepsis; mean age = 50 years, mean APACHE II score = 18, mean ICU stay = 20 days, mean hospital mortality = 44%	Intravenous fluconazole 200 mg/day until resolution of septic shock. Duration of study = 30 months	Hospital mortality, proportion of patients with candidaemia, other fungal infection, proportion of patients requiring rescue therapy using amphotericin B, and proportion of patients colonised with or infected with fluconazole-resistant fungi	Adequate
Ables <i>et al.</i> [20]	Double-blind	119 trauma or after intra-abdominal or intra-thoracic surgery adult patients with at least one of the following: central venous catheter, total parenteral nutrition, mechanical ventilation >24 hours, or treatment with broad-spectrum antibiotics; mean age = 44 years, mean APACHE II score = 18, mean mortality = 19.3%	Either Intravenous, oral, or enteral fluconazole 800 mg loading followed by 400 mg daily (doses adjusted with renal impairment); oral or enteral route was used when there was a presence of bowel sounds and no history of malabsorption. Duration of study = 26 months	Hospital mortality, proportion of patients with candidaemia, proportion of patients with adverse events leading to cessation of the study drug, proportion of patients colonised with or infected with fluconazole-resistant fungi, and total length of hospital stay	Adequate

APACHE acute physiology and chronic health evaluation; ICU, intensive care unit.

Figure 2

Forest plot showing the effect of prophylactic fluconazole on hospital mortality. RR, relative risk; CI, confidence interval.

Figure 3

Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with candidaemia. RR, relative risk; CI, confidence interval.

2114, Australia) was contacted. If necessary, the authors of the identified trials were contacted to obtain additional information and unpublished data that were important in the analysis. No studies published in languages other than English were found in the literature search.


Two independent reviewers examined the titles and the abstracts of all identified trials to confirm they fulfilled the inclusion criteria. They examined and recorded the trial characteristics and outcomes independently, using a predesigned data abstraction form. This abstraction form was used to record information regarding the quality of the trial such as allocation concealment, the randomisation method, blinding of treatment, and the inclusion and exclusion criteria. The grading of allocation concealment was based on the Cochrane approach (i.e. adequate or uncertain or clearly inadequate). Any disagreements between the two independent reviewers were resolved by consensus. Any duplicated publications were combined to represent one single trial. Data were checked and entered into the Review Manager (version 4.2.6 for Windows, 2003; The Cochrane Collaboration, Oxford, UK) database for further analyses.

The hospital mortality and the proportion of patients with candidaemia were chosen as the main outcomes of this meta-analysis because they are the most specific clinically relevant outcomes of invasive fungal infections. There were no missing data for these two main outcomes in the included studies. The other outcomes assessed in this study included the proportion of patients colonised with or infected with fluconazole-resist-


ant fungi, the proportion of patients requiring rescue therapy by systemic amphotericin B treatment, the proportion of patients with an adverse effect requiring cessation of the study drug, the proportion of patients with fungal infections other than urinary tract infection, and the total length of hospital stay. Urinary fungal infection is difficult to distinguish from colonisation, and for this reason these infections were excluded from further analyses in the present study. The definition of prophylaxis failure requiring amphotericin B treatment varied between different studies, but the common definition involved clinical deterioration with positive fungal culture from blood, deep tissue, or sputum.

Statistical analyses

The differences in categorical outcomes between the treatment group and the placebo group were reported as the relative risk (RR) with the 95% confidence interval (CI), using a random effect model. The difference in the total length of hospital stay between the fluconazole group and the placebo group was reported as weight mean difference in days, using a random effect model. The presence of heterogeneity between trials was assessed by chi-square statistics and the extent of inconsistency was assessed by I^2 statistics [14]. Sensitivity analyses were conducted after excluding one study with unclear allocation concealment and one study that recruited some medical patients in the trial. The publication bias was assessed by funnel plot using hospital mortality as an endpoint.

Figure 4

Forest plot showing the effect of prophylactic fluconazole on the proportion of patients with fungal infections. RR, relative risk; CI, confidence interval.

Figure 5

Forest plot showing the effect of fluconazole on proportion of patients colonised with fluconazole-resistant fungi. RR, relative risk; CI, confidence interval.


Results

We identified 16 potentially eligible studies, of which seven studies [13,15-20] fulfilled the inclusion criteria and were subject to meta-analysis (Figure 1). Five studies used the intravenous route [13,15,17-19], one study used the enteral route [16], and one study used either the intravenous or enteral route to administer the study drug depending on the function of the gastrointestinal tract [20]. The doses of fluconazole ranged from 100 to 800 mg/day. One study used a single intraoperative dose of fluconazole [18], and the other six studies used a prolonged course of prophylaxis until recovery from the surgical illness or until a new onset of symptoms or until a positive culture of fungi with the clinical diagnosis of invasive fungal infection. One study recruited patients with acute pancreatitis [19], one study recruited patients with septic shock secondary to intra-abdominal sepsis [13], two studies recruited patients with gut perforation [17,18], and three studies recruited general surgical and trauma patients [15,16,20]. The mean Acute Physiology and Chronic Health Evaluation II and Acute Physiology and Chronic Health Evaluation III scores ranged from 18 to 19 and from 63 to 65, respectively. Six studies had adequate allocation concealment and were definitely double-blinded. The details of all included studies are described in Table 1.

There was a good overall consistency in the results, without significant heterogeneity. The use of prophylactic fluconazole

was associated with a reduction in the proportion of patients with candidaemia (RR = 0.21, 95% CI = 0.06–0.72, $P = 0.01$; $I^2 = 0\%$) and fungal infections other than lower urinary tract infection (RR = 0.39, 95% CI = 0.24–0.65, $P = 0.0003$; $I^2 = 0\%$), but was associated with no significant difference in hospital mortality (RR = 0.82, 95% CI = 0.62–1.08, $P = 0.15$; $I^2 = 7\%$) (Figures 2, 3, 4). The proportion of patients requiring systemic amphotericin B as a rescue therapy for systemic fungal infection was lower after prophylactic use of fluconazole (RR = 0.35, 95% CI = 0.17–0.72, $P = 0.004$; $I^2 = 0\%$). The proportion of patients colonised with or infected with fluconazole-resistant fungi (RR = 0.66, 95% CI = 0.22–1.96, $P = 0.46$; $I^2 = 0\%$) (Figure 5) and the proportion of patients with adverse events leading to cessation of the study drug (RR = 0.75, 95% CI = 0.22–2.58, $P = 0.65$; $I^2 = 0\%$) were not different between the fluconazole group and the placebo group. The total length of hospital stay was no different between the fluconazole group and the placebo group (weight mean difference = -0.4 days, 95% CI = -10.35 to 9.54, $P = 0.94$; $I^2 = 52.4\%$).

Excluding one study with unclear allocation concealment [19] and one study that recruited some medical patients [15] did not affect the magnitude and significance of the results. None of the studies included a formal cost-effectiveness analysis. Five studies received financial grant or drug support from Pfizer Pharmaceuticals, Inc. – of which three studies stated

Figure 6

Funnel plot showing the possibility of a small publication bias. RR, relative risk.

explicitly that the funding agency was not involved in the collection and analyses of the data.

Discussion

Significance of our findings

This meta-analysis shows the benefits of fluconazole prophylaxis on most of the clinically relevant outcomes in critically ill or high-risk surgical patients. Fluconazole prophylaxis is associated with a much lower risk of candidaemia (RR = 0.2) and other candidal infections (RR = 0.4), with less requirement for systemic amphotericin B as a rescue therapy, and with a very safe adverse event profile, and is not associated with a significant increase in fluconazole-resistant fungi. However, we could only observe a trend towards a modest reduction in hospital mortality.

The candidaemia rate of 4.5% in the placebo arm of this meta-analysis is consistent with the estimated risk of candidaemia in patients with at least one risk factor for candidaemia. The risk factors include total parenteral nutrition, acute renal failure, central venous catheter, broad-spectrum antibiotics, immunosuppression, and prior surgery [9]. The beneficial effect of fluconazole on the risk of candidaemia as demonstrated in this meta-analysis is also consistent with the results of a cohort study on critically ill surgical patients [9] and with the results of fluconazole prophylaxis in immunosuppressed patients [30,31]. If our results are valid, the beneficial effect of fluconazole on candidaemia will be stronger than the effect of prophylactic topical non-absorbable antifungal agents such as amphotericin B or nystatin in critically ill patients [32].

Although prophylactic fluconazole is effective in reducing candidaemia, our results did not demonstrate a statistical significant reduction in hospital mortality. However, the candidaemia rate in the placebo arm of this meta-analysis is 4.5% and the expected absolute risk reduction in hospital mortality is about 2.25% if we assume that the attributable mortality of candidae-

mia is 50% [7]. If the 20% RR reduction in hospital mortality as demonstrated in this meta-analysis is valid, a prospective randomised controlled trial (or a meta-analysis) of more than 2,000 patients will be needed to demonstrate such a reduction in hospital mortality, assuming that the baseline hospital mortality of the study population is 25%. The number of patients considered in this meta-analysis was therefore too small to evaluate a mortality difference. The expected smaller treatment effect of prophylactic fluconazole on hospital mortality compared with candidaemia also suggests there are other important factors in determining mortality in patients at high risk of invasive fungal infections [33], and any potential beneficial immunomodulation effect of fluconazole, as suggested by some authors [12,13], is unlikely to be clinically significant in addition to its antifungal activity.

A pharmacoeconomic or cost-effectiveness analysis was not performed in the studies included in this meta-analysis. Based on the baseline risk of candidaemia of 4.5% in the placebo arm of this meta-analysis, the number of patients needed to treat is about 25 to prevent one episode of candidaemia. The cost of 200 mg fluconazole is about US\$35 per day in Australia and Switzerland [17] and a 2-week prophylactic course of fluconazole will therefore cost US\$490 per patient. The cost to prevent one documented episode of candidaemia is estimated to be US\$12,250, which is equivalent to 40% of the economic cost of an episode of candidaemia (US\$30,000) [34]. Prophylactic fluconazole may therefore be potentially cost-effective and justified in some high-risk surgical patients if the candidaemia rate in the selected ICU is high despite optimising other preventive measures such as vigorous hand hygiene, central venous catheter care, and prudent antimicrobial use [7].

Emergence of resistant fungi with widespread use of a prophylactic antifungal agent is a concern even if the drug is cost-effective. Our results did not demonstrate an increase in the risk of colonisation with or infection with fluconazole-resistant

fungi within the time frame of the clinical trials (mean = 29 months, median = 30 months, range = 12–60 months). Whether prophylactic fluconazole will select or induce emergence of fluconazole-resistant fungi in the longer term is still controversial and remains a major consideration before it can be recommended [35–37].

Limitations of the study

Meta-analyses are prone to bias. The quality of trials can affect the direction and magnitude of the treatment effect in meta-analyses. After excluding one study with unclear allocation concealment or double blinding, the direction and magnitude of the results of this meta-analysis remained unchanged. A funnel plot (Figure 6) showed that there was a possibility of a small publication bias, with a lack of small studies showing no effect on mortality with the use of prophylactic fluconazole.

Second, although the results of this meta-analysis were fairly consistent across the included studies, there were significant differences in the diagnoses of the patients and the study protocols, especially in the doses of fluconazole used. The optimal dose and route of administration of fluconazole as a prophylactic agent cannot be evaluated from these pooled studies [32,38].

Conclusion

In immunocompetent high-risk surgical patients, the use of prophylactic fluconazole is associated with a reduced incidence of candidaemia but with only a trend towards reduction in hospital mortality. A large randomised controlled trial would be needed to assess the cost-effectiveness and the risk of inducing fluconazole-resistant fungi before prophylactic fluconazole can be recommended in immunocompetent high-risk surgical patients.

Key messages

- Prophylactic fluconazole was effective in reducing candidaemia in high-risk surgical patients and was associated with a trend towards a reduction in hospital mortality.
- Prophylactic fluconazole was not associated with a significant increase in adverse events or the proportion of patients colonised with or infected with fluconazole-resistant fungi within the time frame of the included studies.

Competing interests

No financial support was received for this study from pharmaceutical companies or other private companies in the form of grants and awards. All authors declare that they have no competing interests in relation to this study.

Authors' contributions

KMH performed the data collection and analyses, and drafted the manuscript. JL and GJD helped with the interpretation of data and drafting the manuscript. SARW performed the data collection, and helped with the interpretation of data and drafting the manuscript.

Acknowledgements

This study was solely funded by the Department of Intensive Care, Royal Perth Hospital. The authors would like to thank Assistant Professor Adrienne Ables for providing data from her study and Ms Lara Mardirossian from Pfizer Australia Pty. Ltd. for providing the reference list of studies evaluating fluconazole.

References

1. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB: **Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study.** *Clin Infect Dis* 2004, **39**:309–317.
2. Lipman J, Saadia R: **Fungal infections in critically ill patients.** *BMJ* 1997, **315**:266–267.
3. Dimopoulos G, Piagnerelli M, Berre J, Eddafali B, Salmon I, Vincent JL: **Disseminated aspergillosis in intensive care unit patients: an autopsy study.** *J Chemother* 2003, **15**:71–75.
4. Tufano R: **Focus on risk factors for fungal infections in ICU patients.** *Minerva Anestesiol* 2002, **68**:269–272.
5. Eggimann P, Garbino J, Pittet D: **Management of Candida species infections in critically ill patients.** *Lancet Infect Dis* 2003, **3**:772–785.
6. Calandra T, Marchetti O: **Clinical trials of antifungal prophylaxis among patients undergoing surgery.** *Clin Infect Dis* 2004, **39 Suppl 4**:S185–S192.
7. Diekema DJ, Pfaller MA: **Nosocomial candidemia: an ounce of prevention is better than a pound of cure.** *Infect Control Hosp Epidemiol* 2004, **25**:624–626.
8. Ostrosky-Zeichner L: **Prophylaxis or preemptive therapy of invasive candidiasis in the intensive care unit?** *Crit Care Med* 2004, **32**:2552–2553.
9. Blumberg HM, Jarvis WR, Soucie JM, Edwards JE, Patterson JE, Pfaller MA, Rangel-Frausto MS, Rinaldi MG, Saiman L, Wiblin RT, Wenzel RP, National Epidemiology of Mycoses Survey (NEMIS) Study Group, et al.: **Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study.** *The National Epidemiology of Mycosis Survey. Clin Infect Dis* 2001, **33**:177–186.
10. Rex JH, Sobel JD: **Prophylactic antifungal therapy in the intensive care unit.** *Clin Infect Dis* 2001, **32**:1191–1200.
11. Lipsett PA: **Clinical trials of antifungal prophylaxis among patients in surgical intensive care units: concepts and considerations.** *Clin Infect Dis* 2004, **39 Suppl 4**:S193–S199.
12. Zervos EE, Fink GW, Norman JG, Robson MC, Rosemurgy AS: **Fluconazole increases bactericidal activity of neutrophils through non-cytokine-mediated pathway.** *J Trauma* 1996, **41**:465–470.
13. Jacobs S, Price Evans DA, Tariq M, Al Omar NF: **Fluconazole improves survival in septic shock: a randomized double-blind prospective study.** *Crit Care Med* 2003, **31**:1938–1946.
14. Higgins JP, Thompson SG, Deeks JJ, Altman DG: **Measuring inconsistency in meta-analyses.** *BMJ* 2003, **327**:557–560.
15. Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D: **Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: a randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination.** *Intensive Care Med* 2002, **28**:1708–1717.
16. Pelz RK, Hendrix CW, Swoboda SM, Diener-West M, Merz WG, Hammond J, Lipsett PA: **Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients.** *Ann Surg* 2001, **233**:542–548.
17. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis G, Chiolerio R, Pannatier A, Schilling J, Geroulanos S, et al.: **Fluconazole**

- zole prophylaxis prevents intra-abdominal candidiasis in high-risk surgical patients. *Crit Care Med* 1999, **27**:1066-1072.
18. Sandven P, Qvist H, Skovlund E, Giercksky KE, NORGAS Group, Norwegian Yeast Study Group: **Significance of Candida recovered from intraoperative specimens in patients with intra-abdominal perforations.** *Crit Care Med* 2002, **30**:541-547.
19. He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q, Chen JW, Lei DX, Jiang CQ, Yuan YF: **Prevention and therapy of fungal infection in severe acute pancreatitis: a prospective clinical study.** *World J Gastroenterol* 2003, **9**:2619-2621.
20. Ables AZ, Blumer NA, Valainis GT, Godenick MT, Kajdasz DK, Palesch YY: **Fluconazole prophylaxis of severe Candida infection in trauma and postsurgical patients: a prospective, double-blind, randomized, placebo-controlled trial.** *Infect Dis Clin Pract* 2000, **9**:169-175.
21. Magill SS, Puthanakit T, Swoboda SM, Carson KA, Salvatori R, Lipsett PA, Hendrix CW: **Impact of fluconazole prophylaxis on cortisol levels in critically ill surgical patients.** *Antimicrob Agents Chemother* 2004, **48**:2471-2476.
22. De Waele JJ, Vogelaers D, Blot S, Colardyn F: **Fungal infections in patients with severe acute pancreatitis and the use of prophylactic therapy.** *Clin Infect Dis* 2003, **37**:208-213.
23. Sandven P, Giercksky KE, NORGAS Group, Norwegian Yeast Study Group: **Yeast colonization in surgical patients with intra-abdominal perforations.** *Eur J Clin Microbiol Infect Dis* 2001, **20**:475-481.
24. Munshi I, Sleeman D, Parra-Davila E, Erbella J, Silva R, Morejon O, Kirton O, Namias N: **Fluconazole prophylaxis in critically ill trauma intensive care unit patients.** *Crit Care Med* 1998, **26**(Suppl):45A.
25. Garrelts JC, Schroeder TR, Harrison PB: **Impact of fluconazole administration on outcomes in critically ill patients.** *Ann Pharmacother* 2004, **38**:1588-1592.
26. Swoboda SM, Merz WG, Lipsett PA: **Candidemia: the impact of antifungal prophylaxis in a surgical intensive care unit.** *Surg Infect (Larchmt)* 2003, **4**:345-354.
27. Fisher NC, Cooper MA, Hastings JG, Mutimer DJ: **Fungal colonization and fluconazole therapy in acute liver disease.** *Liver* 1998, **18**:320-325.
28. Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, Boillot A: **Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients.** *Crit Care Med* 2004, **32**:2443-2449.
29. Gotzinger P, Wamser P, Barlan M, Sautner T, Jakesz R, Fugger R: **Candida infection of local necrosis in severe acute pancreatitis is associated with increased mortality.** *Shock* 2000, **14**:320-323.
30. Marr KA: **Issues in the design of the fluconazole prophylaxis trials in patients undergoing hematopoietic stem cell transplantation.** *Clin Infect Dis* 2004, **39** Suppl 4:S170-S175.
31. Winston DJ, Pakrasi A, Busuttill RW: **Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial.** *Ann Intern Med* 1999, **131**:729-737.
32. Silvestri L, van Saene HK, Milanese M, Gregori D: **Impact of selective decontamination of the digestive tract on fungal carriage and infection: systematic review of randomized controlled trials.** *Intensive Care Med* 2005, **31**:898-910.
33. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW: **Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.** *Clin Infect Dis* 2001, **33**:641-647.
34. Rentz AM, Halpern MT, Bowden R: **The impact of candidemia on length of hospital stay, outcome, and overall cost of illness.** *Clin Infect Dis* 1998, **27**:781-788.
35. Rocco TR, Reinert SE, Simms HH: **Effects of fluconazole administration in critically ill patients: analysis of bacterial and fungal resistance.** *Arch Surg* 2000, **135**:160-165.
36. Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, National Nosocomial Infections Surveillance System Hospitals: **Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999.** *Clin Infect Dis* 2002, **35**:627-630.
37. Pfaller MA, Diekema DJ, International Fungal Surveillance Participant Group: **Twelve years of fluconazole in clinical practice: global trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida.** *Clin Microbiol Infect* 2004, **10** Suppl 1:11-23.
38. Clancy CJ, Yu VL, Morris AJ, Snyderman DR, Nguyen MH: **Fluconazole MIC and the fluconazole dose/MIC ratio correlate with therapeutic response among patients with candidemia.** *Antimicrob Agents Chemother* 2005, **49**:3171-3177.